NEW TRT DRUG IN FINAL STAGES OF STUDY

There’s some big news in the world of testosterone replacement therapy. Antares Pharma Inc announced Wednesday that the first sole self-administered subcutaneous drug has officially started late-stage FDA trials.

QuickShot Testosterone (QST) is the only auto-injector self-administered subcutaneous testosterone (testosterone enanthate) treatment in late-stage development, giving it an edge over existing injectables, which must be administered directly into the muscle by a doctor.

Although there has been a massive surge in research regarding the detrimental effects of low T in males and a remarkable increase in testosterone prescriptions over the past decade, the FDA has become increasingly rigorous in the regulation of testosterone products within recent years.

Although the final results of this current late-stage study aren’t expected until early 2016, Antares Pharma Inc is already seeing gains. After today’s announcement, its shares closed at a higher than normal volume of 6.4 percent—up 4 percent since mid-January.

By: Victoria Felkar